CN1064504A - 康乐霉素c的生产方法 - Google Patents
康乐霉素c的生产方法 Download PDFInfo
- Publication number
- CN1064504A CN1064504A CN91101127A CN91101127A CN1064504A CN 1064504 A CN1064504 A CN 1064504A CN 91101127 A CN91101127 A CN 91101127A CN 91101127 A CN91101127 A CN 91101127A CN 1064504 A CN1064504 A CN 1064504A
- Authority
- CN
- China
- Prior art keywords
- production method
- described production
- concentrated
- culture medium
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/06—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using actinomycetales
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/365—Nocardia
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
康乐霉素C是从一株奴卡氏菌的发酵液中,经
过滤去菌丝,用酸调pH值至酸性,用有机酯类萃取,
将萃取液浓缩后,在硅胶柱上分离用苯和甲醇混合液
洗脱,收集活性部分并浓缩,在LH-20柱上纯化,
用醇类有机溶剂洗脱,收集活性成分并浓缩,用醇类
有机溶剂重结晶即得纯品。该化合物溶于极性有机
溶剂,免疫抑制作用与环孢菌素A相似,并有抗肿瘤
作用,毒性很低。本发明提取工艺简单,化学合成及
结构改造较方便。
Description
本发明涉及一种用于自身免疫溶血性贫血、肾炎、结蹄组织以及脏器移植排斥反应的新免疫抑制剂康乐霉素C的生产方法。
目前开发的免疫抑制剂,其药物选择性强,专一性地调节某一免疫细胞的亚族。代表药物如环孢菌素A,能选择性抑制T辅助细胞的克隆(无性繁殖系)的增殖,在器官移植方面取得了可喜的成绩,并已广泛用于临床。然而,也发现一些副作用,如个别患者用药后出现急性和慢性肾中毒、轻度震颤、神经病变、齿龈肥厚和多毛等副作用。最近发现的FK-506属于大环内酯类抗生素(C44H69NO12),虽然实验研究结果满意,但因生产复杂,限制了临床上广泛应用。
本发明目的在于克服现有免疫抑制剂的各种缺点,寻找更理想替代药物。康乐霉素C的化学结构新颖,有别于迄今所有的免疫抑制剂,分子量小,结构简单,便于修饰。研究表明,康乐霉素C的免疫抑制作用与环孢菌素A相似或稍强,同时有抑制肿瘤细胞的作用,有可能成为更有特点的新一代免疫抑制剂。
本发明的特点是用一株奴卡氏菌进行培养发酵,然后用有机溶剂萃取、柱层析分离和纯化,其条件为:
(1)菌种培养基(%):KNO30.1、NaCl 0.5、K2HPO40.05、FeSO40.01、淀粉2、琼脂1.7、冷开水、PH7.0、28℃培养5~7天;
(2)种子培养基(%):葡萄糖2~5、酵母粉0.1~1.5、kCl 0.1~0.5、黄豆饼粉 0.1~2.5、K2HPO40.01~0.5、(NH4)2SO40.1~2、MgSO40.01~0.1、CaCO30.1~1、自来水100ml、自然PH;
(3)发酵培养基(%):葡萄糖2~5、酵母粉0.5~2、黄豆饼粉0.1~1.5、蛋白胨0.05~0.5、CaCO30.01~1.0、自来水100ml、自然pH。
以上培养基均15磅消毒30分钟备用。将斜面挖块接种于种子培养基摇瓶中(30~70ml装量/250ml),置180~200转/(分钟)旋转摇床,25~32℃培养24~55小时后,以5~15%接种量转入发酵培养基摇瓶(30~100ml装量/500ml),在180~200转/(分钟)旋转摇床25~32℃培养68~96小时供提取用。将发酵液过滤后,用无机酸调pH值在1~5范围,再用乙酸丁酯萃取,萃取液浓缩后,在硅胶柱上分离,用苯和甲醇混合液(30∶1)洗脱,收集活性部分并浓缩,在LH-20柱上纯化用乙醇洗脱,收集活性部分并浓缩,用乙醇重结晶,即得纯品。康乐霉素C为黄色棒状结晶,在170℃分解变成黑色,分子量为326,旋光度为+150°(10-4),紫外光谱中在232纳米,356纳米有最大吸收,红外光谱中在3400cm-1、1690cm-1、1650cm-1、750cm-1等处有吸收,溶于极性有机溶剂,不溶于水和非极性有机溶剂。
0.5μg/ml的康乐霉素C对小鼠脾淋巴细胞转化的抑制率达96.9%。在小鼠脾细胞培养时,康乐霉素C(40μg/ml)没有表现出毒性,在1mg/ml浓度下,对精原细胞无作用。对小鼠静脉注射(2mg/kg)没有发生死亡现象,证明毒性较低。抑制k562白血病细胞增值小于0.1μg/ml,对Hela S3细胞的抑制浓度为1μg/ml。
本发明的优点和积极效果是,目前发现的免疫抑制剂中,康乐霉素C的分子量最小,化学结构全新,提取工艺简单,化学合成及结构改造较方便,免疫抑制作用强,毒性低,因而具有应用推广价值。
图1为康乐霉素C的紫外吸收光谱。
图2为康乐霉素C的红外吸收光谱。
实施例:用一株奴卡氏菌进行培养发酵,然后用有机溶剂萃取、柱层析分离和纯化,其条件为:
(1)菌种培养基(%):KNO30.1、NaCl 0.5、K2HPO40.05、FeSO40.01、淀粉2、琼脂1.7、冷开水、PH7.0、28℃培养5~7天;
(2)种子培养基(%):葡萄糖2.5、酵母粉0.5、kCl 0.25、黄豆饼粉0.5、K2HPO40.02、(NH4)2SO40.5、MgSO40.02、CaCO30.5、自来水100ml、自然PH;
(3)发酵培养基(%):葡萄糖3、酵母粉1、黄豆饼粉0.5、蛋白胨0.2、CaCO30.1、自来水100ml、自然pH。
以上培养基均15磅消毒30分种备用。将斜面挖块接种于种子培养基摇瓶中(50ml装量/250ml),置180~200转/(分钟)旋转摇床,28℃培养48小时后,以10%接种量转入发酵培养基摇瓶(50ml装量/500ml),在180~200转/(分钟)旋转摇床28℃培养72小时供提取用。将发酵液过滤后,用无机酸调pH值到4,再用乙酸丁酯萃取,萃取液浓缩后,在硅胶柱上分离,用苯和甲醇混合液(30∶1)洗脱,收集活性部分并浓缩,在LH-20柱上纯化用乙醇洗脱,收集活性部分并浓缩,用乙醇重结晶,即得纯品。康乐霉素C为黄色棒状结晶,在170℃分解变成黑色,分子量为326,旋光度为+150°(10-4),紫外光谱中在232纳米,356纳米有最大吸收,红外光谱中在3400cm-1、1690cm-1、1650cm-1、750cm-1等处有吸收。溶于极性有机溶剂,不溶于水和非极性有机溶剂。
Claims (7)
1、一种康乐霉素C的生产方法,其特征是用一株奴卡氏菌进行培养、发酵,然后用有机溶剂萃取、柱层析分离和纯化。
2、按权利要求1所述的生产方法,特征是培养和发酵包含菌种培养基、种子培养基、发酵培养基三种培养基和发酵条件。
3、按权利要求2所述的生产方法,其特征是菌种培养条件为KNO30.1%,NaCl0.5%,K2HPO40.05%,FeSO40.01%,淀粉2%,琼脂1.7%,冷开水,pH7.0,28℃培养5~7天。
4、按权利要求2所述的生产方法,其特征是种子培养基条件为葡萄糖2~5%,酵母粉0.1~1.5%,KCl0.1~0.5%,黄豆饼粉0.1~2.5%,K2HPO40.01~0.5%,(NH4)2SO40.1~2%,MgSO40.01~0.1%,CaCO30.1~1%,自来水100ml,自然pH值。
5、按权利要求2所述的生产方法,其特征是发酵培养基条件为葡萄糖2~5%,酵母粉0.5~2%,黄豆饼粉0.1~1.5%,蛋白胨0.05~0.5%,CaCO30.01~1.0%,自来水100ml,自然pH。
6、按权利要求4、5所述的生产方法,其特征是将斜面挖块接种于种子培养基摇瓶中(30~70ml装量/250ml),在180~200转/(分钟)旋转摇床上,25~32℃培养24~55小时后,以5~15%接种量转入发酵培养基摇瓶(30~100ml装量/500ml),在180~200转/(分钟)旋转摇床上25~32℃培养68~96小时供提取用。
7、按权利要求6所述的生产方法,其特征是将发酵液过滤后,用无机酸调pH值1~5范围,再用乙酸丁酯萃取,萃取液浓缩后,在硅胶柱上分离,用苯和甲醇混合液(30∶1)洗脱,收集活性部分并浓缩,在LH-20柱上纯化,用乙醇洗脱,收集活性部分并浓缩,用乙醇重结晶,即得纯品。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN91101127A CN1037526C (zh) | 1991-03-01 | 1991-03-01 | 康乐霉素c的生产方法 |
US07/839,614 US5275817A (en) | 1991-03-01 | 1992-02-21 | Physiologically active kanglemycin C |
CA002061642A CA2061642A1 (en) | 1991-03-01 | 1992-02-21 | Physiologically active kanglemycin c, process for preparing the same and use thereof |
AU11198/92A AU1119892A (en) | 1991-03-01 | 1992-02-24 | Physiologically active kanglemycin c, process for preparing the same and use thereof |
JP4037966A JPH0570470A (ja) | 1991-03-01 | 1992-02-25 | 生理活性物質カンレマイシンc、その製造法及びその薬学的用途 |
EP92103139A EP0501399A1 (en) | 1991-03-01 | 1992-02-25 | Physiologically active kanglemycin C, process for preparing the same and use thereof |
KR1019920002846A KR920018226A (ko) | 1991-03-01 | 1992-02-25 | 생리활성 캉글레마이신 c, 그 제조방법 및 용도 |
HU9200677A HUT63883A (en) | 1991-03-01 | 1992-02-28 | Physiologically active kanglemycin c, process for producing and using same |
IL101103A IL101103A0 (en) | 1991-03-01 | 1992-02-28 | Physiologically active kanglemycin c,process for preparing the same and use thereof |
CS92594A CS59492A3 (en) | 1991-03-01 | 1992-02-28 | Canglemycin c, process of its preparation, its use, a pharmaceutical and astrain for said canglemycin c preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN91101127A CN1037526C (zh) | 1991-03-01 | 1991-03-01 | 康乐霉素c的生产方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1064504A true CN1064504A (zh) | 1992-09-16 |
CN1037526C CN1037526C (zh) | 1998-02-25 |
Family
ID=4904964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN91101127A Expired - Fee Related CN1037526C (zh) | 1991-03-01 | 1991-03-01 | 康乐霉素c的生产方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US5275817A (zh) |
EP (1) | EP0501399A1 (zh) |
JP (1) | JPH0570470A (zh) |
KR (1) | KR920018226A (zh) |
CN (1) | CN1037526C (zh) |
AU (1) | AU1119892A (zh) |
CA (1) | CA2061642A1 (zh) |
CS (1) | CS59492A3 (zh) |
HU (1) | HUT63883A (zh) |
IL (1) | IL101103A0 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003280437A1 (en) * | 2002-06-27 | 2004-01-19 | Microport Medical (Shanghai) Co., Ltd. | Drug eluting stent |
US6908484B2 (en) | 2003-03-06 | 2005-06-21 | Spinecore, Inc. | Cervical disc replacement |
-
1991
- 1991-03-01 CN CN91101127A patent/CN1037526C/zh not_active Expired - Fee Related
-
1992
- 1992-02-21 US US07/839,614 patent/US5275817A/en not_active Expired - Fee Related
- 1992-02-21 CA CA002061642A patent/CA2061642A1/en not_active Abandoned
- 1992-02-24 AU AU11198/92A patent/AU1119892A/en not_active Abandoned
- 1992-02-25 JP JP4037966A patent/JPH0570470A/ja active Pending
- 1992-02-25 EP EP92103139A patent/EP0501399A1/en not_active Withdrawn
- 1992-02-25 KR KR1019920002846A patent/KR920018226A/ko not_active Application Discontinuation
- 1992-02-28 IL IL101103A patent/IL101103A0/xx unknown
- 1992-02-28 CS CS92594A patent/CS59492A3/cs unknown
- 1992-02-28 HU HU9200677A patent/HUT63883A/hu unknown
Also Published As
Publication number | Publication date |
---|---|
JPH0570470A (ja) | 1993-03-23 |
KR920018226A (ko) | 1992-10-21 |
AU1119892A (en) | 1992-09-03 |
HU9200677D0 (en) | 1992-05-28 |
CS59492A3 (en) | 1992-09-16 |
CN1037526C (zh) | 1998-02-25 |
IL101103A0 (en) | 1992-11-15 |
EP0501399A1 (en) | 1992-09-02 |
HUT63883A (en) | 1993-10-28 |
CA2061642A1 (en) | 1992-09-02 |
US5275817A (en) | 1994-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS608117B2 (ja) | 新生理活性物質エステラスチンおよびその製造法 | |
JPH0615555B2 (ja) | 抗生物質ゾフイマリン | |
CN101720772B (zh) | 一种防治作物真菌病害的大环内脂类组合物及其制备工艺 | |
EP0371509B1 (en) | Antibiotics and process for producing them | |
CN1037526C (zh) | 康乐霉素c的生产方法 | |
JPS60259191A (ja) | Cl−1724抗微生物/抗腫瘍化合物、その製造および用途 | |
CA1264691A (en) | Antibiotic crisamicin a and compositions thereof | |
CN107226801A (zh) | 一种xanthone类化合物及其单晶的制备方法与作为α-葡萄糖苷酶抑制剂的应用 | |
CN102452916B (zh) | 一类芳香聚酮及其提取方法和应用 | |
JPH03141290A (ja) | 抗腫瘍抗生物質bmy―41339 | |
KR940004128B1 (ko) | 혈소판 활성화 인자 길항 물질인 "포막틴(phomactins)", 그의 제조방법 및 용도 | |
JPS6084220A (ja) | 植物病原菌リゾ−プス・キネンシスの代謝産物リゾキシンを有効成分とする抗腫瘍剤 | |
CN108516923B (zh) | 一系列烯萜类化合物及其制备方法和应用 | |
JP2837870B2 (ja) | 新規な制癌抗生物質コナゲニン及びその製造法 | |
CA2016084A1 (en) | New microbial transformation product | |
CN114605247A (zh) | 一种二萜类衍生物及其制备方法与镇痛药物、小脆柄菇发酵得物及其乙酸乙酯萃取液 | |
JPH0367077B2 (zh) | ||
EP0187528B1 (en) | A new compound fr-68504, production thereof and use thereof | |
CN116410185A (zh) | 嗜氮酮类化合物及其制备方法和在制备神经退行性疾病药物中的应用 | |
JP2990628B2 (ja) | 新規植物生長調節物質aji−302及びその製造法 | |
KR800000895B1 (ko) | 럭크노마이신의 제법 | |
JP2001002649A (ja) | 生理活性物質 | |
JPH0429995A (ja) | 新規抗生物質wf3010およびその製造法 | |
JPH05163289A (ja) | 新規な免疫抑制物質、mi710−51f6物質およびその製造法 | |
JPS5934358B2 (ja) | 抗生物質ナナオマイシンaの誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
OR01 | Other related matters | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |